Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2017

View Archived Issues

CinRx closes Series B financing

Carrick initiates phase I program with CDK7 inhibitor CT-7001

Patient recruitment ongoing in phase I/II trial of PCM-075 in patients with AML

First-in-human phase I trial of AMG-701 enrolling patients with multiple myeloma

NIH and partners launch Imbokodo HIV vaccine trial

Orpheris announces the results of meeting with the FDA regarding regulatory path for OP-101

Cardiac Hsl gene knockdown provides model of hypoxia tolerance

MicroRNA-4639 a potential plasma biomarker of early Parkinson's disease

Phase I study of PGDM-1400 and PGT-121 mAbs in HIV-infected and HIV-uninfected adults

EMA validates application for Opdivo plus Yervoy in advanced renal cell carcinoma

Serum CETP may identify mortality risk in hemodialysis patients

Solid Biosciences initiates IGNITE DMD phase I/II study of SGT-001

Zhejiang Hisun Pharmaceutical presents new epothilone derivatives

Luoda Biosciences and Nanjing Shiqi Pharmaceutical describe novel anticancer compounds

FDA approves FoundationOne CDx diagnostic test

Novel AMP-activated protein kinase activators generated at Shionogi

Enanta patents novel farnesoid X receptor agonists

Mavupharma Series A financing to fund STING Modulators

FDA approves once-monthly Sublocade to treat opioid use disorder

FDA grants fast track to Armagen's AGT-181 for the treatment of patients with Hurler syndrome

Astellas Pharma exercises option to acquire Mitobridge

U.K.'s MHRA reclassifies Viagra for sale as non-prescription, pharmacy medicine

Astellas files for Japanese approval of Gonax 12-week formulation for prostate cancer

Afstyla launched in Japan for the treatment of hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...